So far, a total of seven GLP-1 RAs, including exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide, semaglutide, and tirzepatide, have been approved by the US Food and Drug Administration (FDA) for treatment of T2DM. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.